Modeling Disease with Human Inducible Pluripotent Stem Cells.
View / Open Files
Publication Date
2019-01-24Journal Title
Annu Rev Pathol
ISSN
1553-4006
Publisher
Annual Reviews
Volume
14
Pages
449-468
Language
eng
Type
Article
This Version
AM
Physical Medium
Print-Electronic
Metadata
Show full item recordCitation
Grandy, R., Tomaz, R. A., & Vallier, L. (2019). Modeling Disease with Human Inducible Pluripotent Stem Cells.. Annu Rev Pathol, 14 449-468. https://doi.org/10.1146/annurev-pathol-020117-043634
Abstract
Understanding the physiopathology of disease remains an essential step in developing novel therapeutics. Although animal models have certainly contributed to advancing this enterprise, their limitation in modeling all the aspects of complex human disorders is one of the major challenges faced by the biomedical research field. Human induced pluripotent stem cells (hiPSCs) derived from patients represent a great opportunity to overcome this deficiency because these cells cover the genetic diversity needed to fully model human diseases. Here, we provide an overview of the history of hiPSC technology and discuss common challenges and approaches that we and others have faced when using hiPSCs to model disease. Our emphasis is on liver disease, and consequently, we review the progress made using this technology to produce functional liver cells in vitro and how these systems are being used to recapitulate a diversity of developmental, metabolic, genetic, and infectious liver disorders.
Keywords
Hepatocytes, Humans, Cell Differentiation, Models, Biological, Induced Pluripotent Stem Cells
Sponsorship
Medical Research Council (MC_PC_12009)
National Centre for the Replacement Refinement and Reduction of Animals in Research (NC/N001540/1)
Identifiers
External DOI: https://doi.org/10.1146/annurev-pathol-020117-043634
This record's URL: https://www.repository.cam.ac.uk/handle/1810/286576
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.